Trulieve to Begin NYSE Trading June 2026 After Schedule III Move

Trulieve Cannabis Corp. will begin trading on the New York Stock Exchange under the ticker symbol "TRLV" on June 10, 2026, the Florida-based multi-state operator announced last week—marking a watershed moment for cannabis companies seeking access to major U.S. exchanges.

The move follows the Drug Enforcement Administration's rescheduling of cannabis from Schedule I to Schedule III under the Controlled Substances Act, a regulatory shift that removed key barriers preventing marijuana companies from listing on premier exchanges like the NYSE and Nasdaq.

Trulieve currently trades on the Canadian Securities Exchange and over-the-counter markets in the United States, a common arrangement for cannabis operators locked out of major American exchanges due to federal prohibition. The company operates 196 dispensaries across 11 states and reported $1.3 billion in revenue for fiscal 2025.

The Schedule III Effect

The rescheduling decision, finalized in March 2026, reclassified cannabis alongside drugs like ketamine and anabolic steroids—substances recognized as having medical value but still subject to federal control. While cannabis remains federally regulated, the Schedule III designation opened pathways for state-licensed operators to access traditional banking services and capital markets previously off-limits.

"This represents the single most significant development for cannabis capital markets since Canada legalized adult-use in 2018," said Emily Chen, managing director at Viridian Capital Advisors. "We're watching decades of financial exclusion begin to unwind."

The NYSE and Nasdaq both updated their listing requirements in April 2026 to accommodate Schedule III cannabis companies operating under state licenses. Requirements include demonstrated compliance with state regulations, audited financials meeting SEC standards, and minimum market capitalization thresholds—all criteria Trulieve already meets.

Market Implications

Trulieve's announcement sent ripples through cannabis equity markets. Shares of the company rose 8% on the CSE following the NYSE news, while competitors including Curaleaf, Green Thumb Industries, and Cresco Labs saw gains of 3-5% as investors anticipated similar moves.

"Trulieve is testing the waters, but they won't be alone for long," said Aaron Smith, co-founder of the National Cannabis Industry Association. "Every major MSO has been preparing for this moment. Expect a wave of up-listings over the next 12 months."

Access to the NYSE provides cannabis companies with expanded investor pools, improved liquidity, and enhanced credibility with institutional investors who previously avoided the sector due to federal illegality concerns. The exchange listing also eliminates the liquidity discount that has plagued OTC-traded cannabis stocks for years.

What's Next

Trulieve must still complete the NYSE's formal approval process, which includes review of the company's financial statements, corporate governance structure, and compliance history. The company said it expects to satisfy all listing requirements well ahead of the June target date.

Other multi-state operators have signaled plans to pursue similar listings. Curaleaf Holdings CEO Matt Darin told analysts during an April earnings call that the company is "actively engaged" with both the NYSE and Nasdaq regarding potential listings in late 2026 or early 2027.

The Schedule III rescheduling also restored cannabis companies' ability to deduct ordinary business expenses under Section 280E of the tax code, a change expected to improve operator profitability by 20-30% according to industry analysts. Combined with improved capital access, the regulatory shifts position the sector for significant expansion.

Trading on a major exchange won't eliminate all challenges facing cannabis companies. Interstate commerce remains prohibited, forcing operators to maintain state-by-state operations. Banking access, while improved, still faces hurdles as many institutions remain cautious about cannabis relationships.

But for Trulieve and its peers, June 10 represents a milestone that seemed impossible just two years ago—a date when cannabis finally joins mainstream American finance.

---

This article is based on original reporting by ganjapreneur.com.